Moderna stock climbed after the deadly hantavirus outbreak drew investors' attention to the company's ongoing infectious ...

RSV and flu mRNA vaccines struggle with lower durability, higher side effects, and weak uptake, leading to program cuts and ...

Annika Kim Constantino, CNBC’s healthcare reporter, says Moderna’s hantavirus vaccine research remains in early stages, while ...

Moderna's early hantavirus vaccine research has boosted stock price, reflecting market interest. The vaccine is in initial ...

An mRNA-based flu shot could make a huge difference in flu prevention, allowing scientists to pick a better strain match.

Shares of Moderna ( MRNA) were up nearly 7% in recent trading, following a 12% jump Friday, after Bloomberg reported the ...

March 4 (Reuters) - Moderna shares rose ⁠9% ⁠on Wednesday after it settled ⁠a long-running legal battle over the technology that made its COVID-19 vaccine possible, removing an overhang and allowing ...

Marjorie Taylor Greene and other conservative commentators have claimed that Moderna is developing a hantavirus mRNA vaccine.

After a large trial showed stronger protection, regulators are weighing whether Moderna’s mRNA vaccine could become a U.S.

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...